Cellergy Bio
Founded 2022 · 16 employees on LinkedIn · 1 known investors
Cellergy develops allogeneic mitochondrial transplantation therapy, producing GMP-grade purified mitochondria from human primary cells for intravenous, repeated administration. Its therapy targets systemic and degenerative conditions such as CNS disorders, muscle degeneration, and aging, and uses a machine-learning model to predict donor/recipient matching.
Investors · 1
Frequently asked questions
- What does Cellergy Bio do?
- Cellergy develops allogeneic mitochondrial transplantation therapy, producing GMP-grade purified mitochondria from human primary cells for intravenous, repeated administration. Its therapy targets systemic and degenerative conditions such as CNS disorders, muscle degeneration, and aging, and uses a machine-learning model to predict donor/recipient matching.
- Who are Cellergy Bio's investors?
- Cellergy Bio's investors include fresh.fund.